Nantong Yishi Biotechnology Co., Ltd. established the Yijianshi brand in 2002, from the initial service to women of childbearing age to the current service scope to reproductive eugenics, prenatal screening, venereal disease testing, hepatitis testing, tumor marker testing, For drug testing and other services, the Ekins brand has always been committed to human health testing services. Ekins, be your health guardian!

Nantong Yishi Biotechnology Co., Ltd. (hereinafter referred to as "Yish Biotechnology") was established in 1999. It is a national high-tech enterprise integrating biological raw material development, diagnostic reagent manufacturing, domestic and foreign trade, and services. The company has established Yishi Biological Research Institute and Beijing, Wuxi and Zhengzhou R&D centers, mainly conducting research and development of in vitro diagnostic reagents, nano-antibody, gene recombinant antigen, monoclonal antibody, polymerase chain reaction reagent (PCR), detection equipment and Production. The company is at the forefront of the industry in many fields such as family reproductive health testing, drug testing and drug abuse, infectious disease testing, and tumor diagnosis.

Yishi Biologics has passed ISO9001, ISO14001, ISO45001, ISO13485 quality system certification, MDSAP system, and BRC system certification. In order to accelerate the industrial layout, Yishi Bioscience and Clinical Diagnostic Reagent Co., Ltd. has successively held Beijing Najie Diagnostic Reagent Co., Ltd. and Wuxi Ouplan Technology Co., Ltd. in 2021. Yishi Bio currently participates in the controlling stake in a total of 25 companies, forming a closed-loop industrial chain centered on Yishi Biotech, integrating raw material development, product research and development, production, testing, diagnosis, domestic and foreign trade, and services.

Thanks to Yishi Bio's platform-based, standardized and cooperative R&D design management system, the company and its subsidiaries currently own 30 invention patents, 60 utility model patents, and 23 national patents under review. In the future, Yishi Biotech will continue to focus on life sciences, serve human health, and continue to provide you with more professional, more complete and better scientific diagnostic and testing solutions. We strive to become a leader in the field of family reproductive health testing and a major participant in China's drug control industry. We have become an important influential comprehensive service provider in clinical rapid immune testing, infectious disease testing, tumor diagnosis, etc. Empowered to create an international, advanced and rapidly developing IVD R&D, manufacturing and service platform.